ON THIS PAGE: You will learn about the different types of treatments doctors use to treat people with kidney cancer. Use the menu to see other pages.
This section explains the types of treatments that are the standard of care for kidney cancer. “Standard of care” means the best treatments known. When making treatment plan decisions, you are encouraged to consider clinical trials as an option. A clinical trial is a research study that tests a new approach to treatment. Doctors want to learn whether the new treatment is safe, effective, and possibly better than the standard treatment. Clinical trials can test a new drug, a new combination of standard treatments, or new doses of standard drugs or other treatments. Clinical trials are an option to consider for treatment and care for all stages of cancer. Your doctor can help you consider all your treatment options. Learn more about clinical trials in the About Clinical Trials and Latest Research sections of this guide.
In cancer care, different types of doctors often work together to create a patient’s overall treatment plan that combines different types of treatments. This is called a multidisciplinary team. For kidney cancer, the health care team usually includes these individuals:
Urologist. A doctor who specializes in the genitourinary tract, which includes the kidneys, bladder, genitals, prostate, and testicles.
Urologic oncologist. A urologist who specializes in treating cancers of the urinary tract.
Medical oncologist. A doctor trained to treat cancer with systemic treatments using medications.
Radiation oncologist. A doctor trained to treat cancer with radiation therapy. This doctor will be part of the team if radiation therapy is recommended.
Cancer care teams include a variety of other health care professionals, such as physician assistants, nurse practitioners, oncology nurses, social workers, pharmacists, counselors, dietitians, and others.
Descriptions of the common types of treatments used for kidney cancer are listed below. Your care plan also includes treatment for symptoms and side effects, an important part of cancer care.
Treatment options and recommendations depend on several factors, including the cell type and stage of cancer, possible side effects, and the patient’s preferences and overall health. Take time to learn about all of your treatment options and be sure to ask questions about things that are unclear. Talk with your doctor about the goals of each treatment and what you can expect while receiving treatment. These types of talks are called “shared decision making.” Shared decision making is when you and your doctors work together to choose treatments that fit the goals of your care. Shared decision making is particularly important for kidney cancer because there are different treatment options. Learn more about making treatment decisions.
Kidney cancer is most often treated with surgery, targeted therapy, immunotherapy, or a combination of these treatments. Radiation therapy and chemotherapy are occasionally used. People with kidney cancer that has spread, called metastatic cancer (see below), often receive multiple lines of therapy. This means treatments are given one after another.
Sometimes the doctor may recommend closely monitoring the tumor with regular diagnostic tests and clinic appointments. This is called "active surveillance." Active surveillance is effective in older adults and people who have a small renal tumor and another serious medical condition, such as heart disease, chronic kidney disease, or severe lung disease. Active surveillance may also be used for some people with kidney cancer as long as they are otherwise well and have few or no symptoms, even if the cancer has spread to other parts of the body. Systemic therapies (see "Therapies using medication," below) can be started if it looks like the disease is getting worse.
Active surveillance is not the same as "watchful waiting" for kidney cancer. Watchful waiting involves regular appointments to review symptoms, but patients do not have regular diagnostic tests, such as biopsy or imaging scans. The doctor simply watches for symptoms. If symptoms suggest that action is needed, then a new treatment plan is considered.
Surgery is the removal of the tumor and some surrounding healthy tissue during an operation. If the cancer has not spread beyond the kidneys, surgery to remove the tumor may be the only treatment needed. Surgery to remove the tumor may mean removing part or all of the kidney, as well as possibly nearby tissue and lymph nodes.
Types of surgery used for kidney cancer include the following procedures:
Radical nephrectomy. Surgery to remove the tumor, the entire kidney, and surrounding tissue is called a radical nephrectomy. If nearby tissue and surrounding lymph nodes are also affected by the disease, a radical nephrectomy and lymph node dissection is performed. During a lymph node dissection, the lymph nodes affected by the cancer are removed. If the cancer has spread to the adrenal gland or nearby blood vessels, the surgeon may remove the adrenal gland during a procedure called an adrenalectomy, as well as parts of the blood vessels. A radical nephrectomy is usually recommended to treat a large tumor when there is not much healthy tissue remaining. Sometimes the renal tumor will grow directly inside the renal vein and enter the vena cava on its way to the heart. If this happens, complex cardiovascular surgical techniques are needed.
Partial nephrectomy. A partial nephrectomy is the surgical removal of the tumor. This type of surgery preserves kidney function and lowers the risk of developing chronic kidney disease after surgery. Research has shown that partial nephrectomy is effective for T1 tumors whenever surgery is possible. Newer approaches that use a smaller surgical incision, or cut, are associated with fewer side effects and a faster recovery.
Laparoscopic and robotic surgery (minimally invasive surgery). During laparoscopic surgery, the surgeon makes several small cuts in the abdomen, rather than the one larger cut used during a traditional surgical procedure. The surgeon then inserts telescoping equipment into these small keyhole incisions to completely remove the kidney or perform a partial nephrectomy. Sometimes, the surgeon may use robotic instruments to perform the operation. This surgery may take longer but may be less painful. Laparoscopic and robotic approaches require specialized training. It is important to discuss the potential benefits and risks of these types of surgery with your surgical team and to be certain that the team has experience with the procedure.
Before any type of surgery, talk with your health care team about the possible side effects from the specific surgery you will have. Learn more about the basics of cancer surgery.
Non-surgical tumor treatments
Sometimes surgery is not recommended because of characteristics of the tumor or the patient’s overall health. Every patient should have a thorough conversation with their doctor about their diagnosis and risk factors to see if these treatments are appropriate and safe for them. The following procedures may be recommended:
Radiofrequency ablation. Radiofrequency ablation (RFA) is the use of a needle inserted into the tumor to destroy the cancer with an electrical current. The procedure is performed by an interventional radiologist or urologist. The patient is sedated and given local anesthesia to numb the area. In the past, RFA has only been used for people who were too sick to have surgery. Today, most of these patients are monitored with active surveillance (see above).
Cryoablation. Cryoablation, also called cryotherapy or cryosurgery, is the freezing of cancer cells with a metal probe inserted through a small incision. The metal probe is placed into the cancerous tissue. A CT scan and ultrasound are used to guide the probe. The procedure requires general anesthesia for several hours and is performed by an interventional radiologist. Some surgeons combine this technique with laparoscopy to treat the tumor, but there is not much long-term research evidence to prove that it is effective.
Therapies using medication
Systemic therapy is the use of medication to destroy cancer cells. This type of medication is given either by mouth or directly through the bloodstream to reach cancer cells throughout the body. Systemic therapies are generally prescribed by a medical oncologist, a doctor who specializes in treating cancer with medication.
Common ways to give systemic therapies include an intravenous (IV) tube placed into a vein using a needle or in a pill or capsule that is swallowed (orally).
The types of systemic therapies used for kidney cancer include:
Each of these types of therapies is discussed below in more detail. A person may receive 1 type of systemic therapy at a time or a combination of systemic therapies given at the same time. They can also be given as part of a treatment plan that includes surgery and/or radiation therapy.
The medications used to treat cancer are continually being evaluated. Talking with your doctor is often the best way to learn about the medications prescribed for you, their purpose, and their potential side effects or interactions with other medications. It is also important to let your doctor know if you are taking any other prescription or over-the-counter medications or supplements. Herbs, supplements, and other drugs can interact with cancer medications. Learn more about your prescriptions by using searchable drug databases.
Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and limits damage to healthy cells.
Not all tumors have the same targets. Research studies continue to find out more about specific molecular targets and new treatments directed at them. Learn more about the basics of targeted treatments.
Targeted therapies for kidney cancer are described below.
Anti-angiogenesis therapy (updated 03/2021). This type of treatment focuses on stopping angiogenesis, which is the process of making new blood vessels. Most clear cell kidney cancers have mutations of the VHL gene, which causes the cancer to make too much of a certain protein, known as vascular endothelial growth factor (VEGF). VEGF controls the formation of new blood vessels and can be blocked with certain drugs. Because a tumor needs the nutrients delivered by blood vessels to grow and spread, the goal of anti-angiogenesis therapies is to “starve” the tumor. There are 2 ways to block VEGF, with small molecule inhibitors of the VEGF receptors (VEGFR) or with antibodies directed against these receptors.
One antibody called bevacizumab (Avastin) has been shown to slow tumor growth for people with metastatic renal cell carcinoma. Bevacizumab combined with interferon (see “Immunotherapy,” below) slows tumor growth and spread. There are 2 similar drugs, called bevacizumab-awwb (Mvasi) and bevacizumab-bvzr (Zirabev), that have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic kidney cancer. These are called biosimilars, and they are similar in their action to the original bevacizumab antibody.
The other way to block VEGF is with tyrosine kinase inhibitors (TKIs). Axitinib (Inlyta), cabozantinib (Cabometyx), pazopanib (Votrient), lenvatinib (Lenvima), sorafenib (Nexavar), sunitinib (Sutent), and tivozanib (Fotivda) are TKIs that block VEGF receptors. They may be used to treat clear cell kidney cancer. Common side effects of TKIs may include diarrhea, high blood pressure, and tenderness and sensitivity in the hands and feet. Of these approved treatments, pazopanib, sunitinib, or cabozantinib are often used as first-line treatments. Axitinib or cabozantinib maybe be used as first-line treatments combined with immunotherapies (see below). After first-line treatment, axitinib, cabozantinib, lanvatinib, and tivozanib may be recommended, if they have not already been used.
mTOR inhibitors. Everolimus (Afinitor) and temsirolimus (Torisel) are drugs that target a certain protein that helps kidney cancer cells grow, called mTOR. Studies show that these drugs slow kidney cancer growth.
HIF2a inhibitor (updated 08/2021). Belzutifan (Welireg) is a drug that targets hypoxia-inducible factor-2 alpha (HIF2a), which is a protein that can support the growth of blood vessels and cancer cells. Belzutifan can be used to treat renal cell carcinoma in people with von Hippel-Lindau syndrome.
Combined therapies (updated 08/2021). In 2019, the FDA approved 2 combination treatments for the first treatment for advanced renal cell carcinoma. The first combination includes axitinib and pembrolizumab (Keytruda), which is an immune checkpoint inhibitor (see "Immunotherapy," below). The second combination uses axitinib and avelumab (Bavencio), which is another immune checkpoint inhibitor. Axitinib is an anti-angiogenesis therapy. Both pembrolizumab and avelumab target the PD-1 pathway to activate the immune system to attack cancer cells.
In 2021, the FDA approved 2 more combination treatments for the first treatment of advanced renal cell carcinoma: cabozantinib (an anti-angiogenesis therapy) with nivolumab (an immune checkpoint inhibitor blocking the PD-1 pathway) and lenvatinib (also an anti-angiogenesis therapy) with pembrolizumab. These treatment combinations work regardless of whether the tumor expresses the PD-L1 protein, so people who receive this treatment will not be tested for PD-L1. While all of these treatments were approved based on superior outcomes compared to sunitinib, none of the combinations have been compared directly to each other. Therefore, the doctor will help select the most appropriate treatment option for each patient based on their unique situation.
Talk with your doctor about possible side effects for each specific medication and how they can be managed.
Immunotherapy, also called biologic therapy, is designed to boost the body's natural defenses to fight cancer. It uses materials made either by the body or in a laboratory to improve, target, or restore immune system function.
Interleukin-2 (IL-2, Proleukin). IL-2 is a type of immunotherapy that has been used to treat later-stage kidney cancer. It is a cytokine, which is a protein produced by white blood cells. It is important in immune system function, including the destruction of tumor cells.
High-dose IL-2 can cause severe side effects, such as low blood pressure, excess fluid in the lungs, kidney damage, heart attack, bleeding, chills, and fever. Patients may need to stay in the hospital for up to 10 days during treatment. However, some symptoms may be reversible. Only centers with expertise in high-dose IL-2 treatment for kidney cancer should recommend IL-2. High-dose IL-2 can cure a small percentage of people with metastatic kidney cancer. Some centers use low-dose IL-2 because it has fewer side effects, but it is not as effective.
Alpha-interferon. Alpha-interferon is used to treat kidney cancer that has spread. Interferon appears to change the proteins on the surface of cancer cells and slow their growth. Although it has not proven to be as beneficial as IL-2, alpha-interferon has been shown to lengthen lives when compared with an older treatment called megestrol acetate (Megace).
Immune checkpoint inhibitors. A type of immunotherapy called immune checkpoint inhibitors is being studied in kidney cancer. The FDA has approved a combination of 2 immune checkpoint inhibitors, nivolumab (Opdivo) and ipilimumab (Yervoy), to treat certain patients with advanced renal cell carcinoma that has not been previously treated. Nivolumab may also be used in combination with cabozantinib (a targeted therapy, see “Anti-angiogenesis therapy” above) as a first-line treatment for advanced renal cell carcinoma. In addition, the FDA has also approved combinations of a checkpoint inhibitor, pembrolizumab (Keytruda) or avelumab (Bavencio), plus a targeted therapy, axitinib (see "Targeted Therapy," above), as a first-line treatment for people with advanced renal cell carcinoma. These approvals were based on large clinical trials showing the benefit of the immunotherapy combinations over sunitinib in people with advanced or metastatic kidney cancer. Additional research had previously shown that nivolumab given as a single drug through the vein every 2 weeks also helped certain people who had received prior anti-angiogenesis treatments live longer than patients treated with the targeted therapy everolimus. There are several ongoing clinical trials investigating immune checkpoint inhibitors for the treatment of kidney cancer (see Latest Research).
Different types of immunotherapy can cause different side effects. Common side effects include skin reactions, flu-like symptoms, diarrhea, and weight changes. Talk with your doctor about possible side effects for the immunotherapy recommended for you. Learn more about the basics of immunotherapy.
Chemotherapy is the use of drugs to destroy cancer cells, usually by keeping the cancer cells from growing, dividing, and making more cells.
A chemotherapy regimen, or schedule, usually consists of a specific number of cycles given over a set period of time. A patient may receive 1 drug at a time or a combination of different drugs given at the same time.
Although chemotherapy is useful for treating many types of cancer, most cases of kidney cancer are resistant to chemotherapy. Researchers continue to study new drugs and new combinations of drugs. For some patients, the combination of gemcitabine (Gemzar) with capecitabine (Xeloda) or fluorouracil (5-FU) will temporarily shrink a tumor.
The side effects of chemotherapy depend on the individual and the dose used, but can include fatigue, risk of infection, nausea and vomiting, hair loss, loss of appetite, and diarrhea. These side effects usually go away after treatment is finished.
Learn more about the basics of chemotherapy.
Radiation therapy is the use of high-energy x-rays or other particles to destroy cancer cells. A doctor who specializes in giving radiation therapy to treat cancer is called a radiation oncologist.
Radiation therapy is not effective as a primary treatment for kidney cancer. It is very rarely used alone to treat kidney cancer because of the damage it causes to the healthy kidney. Radiation therapy is used only if a patient cannot have surgery and, even then, usually only on areas where the cancer has spread and not on the primary kidney tumor. Most often, radiation therapy is used when the cancer has spread. This is done to help ease symptoms, such as bone pain or swelling in the brain.
Learn more about the basics of radiation therapy.
Physical, emotional, and social effects of cancer
Cancer and its treatment cause physical symptoms and side effects, as well as emotional, social, and financial effects. Managing all of these effects is called palliative care or supportive care. It is an important part of your care that is included along with treatments intended to slow, stop, or eliminate the cancer.
Palliative care focuses on improving how you feel during treatment by managing symptoms and supporting patients and their families with other, non-medical needs. Any person, regardless of age or type and stage of cancer, may receive this type of care. And it often works best when it is started right after a cancer diagnosis. People who receive palliative care along with treatment for the cancer often have less severe symptoms, better quality of life, and report that they are more satisfied with treatment.
Palliative treatments vary widely and often include medication, nutritional changes, relaxation techniques, emotional and spiritual support, and other therapies. You may also receive palliative treatments similar to those meant to get rid of the cancer, such as surgery or radiation therapy.
Before treatment begins, talk with your doctor about the goals of each treatment in the treatment plan. You should also talk about the possible side effects of the specific treatment plan and palliative care options.
During treatment, your health care team may ask you to answer questions about your symptoms and side effects and to describe each problem. Be sure to tell the health care team if you are experiencing a problem. This helps the health care team treat any symptoms and side effects as quickly as possible. It can also help prevent more serious problems in the future.
Metastatic kidney cancer
If cancer spreads to another part in the body from where it started, doctors call it metastatic cancer.
Metastatic kidney cancer most commonly spreads to the lungs, but it can also spread to the lymph nodes, bones, liver, brain, skin, and other areas in the body. This is a systemic disease that requires systemic therapy, such as targeted therapy or immunotherapy. Currently, the most effective treatment for metastatic kidney cancer is often immunotherapy combinations that activate the immune system to attack cancer cells. These drugs have been shown to lengthen life when compared with standard treatment. Sometimes, doctors may ask a surgeon to remove the kidney with the tumor in an operation called a cytoreductive nephrectomy. This prevents pain and bleeding during systemic treatment and may be recommended for certain patients. For kidney cancer that has spread to 1 specific part of the body, such as a single spot in the lung, surgery may be able to completely remove the cancer. This operation is called a metastasectomy, and it can help some people live longer. If the cancer has spread to many areas beyond the kidney, it is more difficult to treat. Surgery is often not helpful, and systemic therapy using medications may be given instead.
If the cancer has spread, it is a good idea to talk with doctors who have experience in treating it. Doctors can have different opinions about the best standard treatment plan. Clinical trials might also be an option. Learn more about getting a second opinion before starting treatment, so you are comfortable with your chosen treatment plan. Palliative care is also important to help relieve symptoms and side effects.
For most people, a diagnosis of metastatic cancer is very stressful and difficult. You and your family are encouraged to talk about how you feel with doctors, nurses, social workers, or other members of the health care team. It may also be helpful to talk with other patients, including through a support group.
Remission and the chance of recurrence
A remission is when cancer cannot be detected in the body and there are no symptoms. This may also be called having “no evidence of disease” or NED.
A remission may be temporary or permanent. This uncertainty causes many people to worry that the cancer will come back. While many remissions are permanent, it is important to talk with your doctor about the possibility of the cancer returning. Understanding your risk of recurrence and the treatment options may help you feel more prepared if the cancer does return. Learn more about coping with the fear of recurrence.
If the cancer returns after the original treatment, it is called recurrent cancer. It may come back in the same place (called a local recurrence), nearby (regional recurrence), or in another place (distant recurrence). If you have had a partial nephrectomy already, a new tumor may form in the same kidney. The recurrent tumor can be removed with another partial nephrectomy or with a radical nephrectomy (see "Surgery," above).
When there is a recurrence, a new cycle of testing will begin to learn as much as possible about the recurrence. After this testing is done, you and your doctor will talk about the treatment options. Often the treatment plan will include the treatments described above, such as surgery, targeted therapy, or immunotherapy, but they may be used in a different combination or given at a different pace. Your doctor may also suggest clinical trials that are studying newly developed systemic therapies or new combinations of such drugs. Whichever treatment plan you choose, palliative care will be important for relieving symptoms and side effects.
People with recurrent cancer often experience emotions such as disbelief or fear. You are encouraged to talk with the health care team about these feelings and ask about support services to help you cope. Learn more about dealing with cancer recurrence.
If treatment does not work
Recovery from cancer is not always possible. If the cancer cannot be cured or controlled, the disease may be called advanced or terminal.
This diagnosis is stressful, and for many people, advanced cancer is difficult to discuss. However, it is important to have open and honest conversations with your health care team to express your feelings, preferences, and concerns. The health care team has special skills, experience, and knowledge to support patients and their families and is there to help. Making sure a person is physically comfortable, free from pain, and emotionally supported is extremely important.
People who have advanced cancer and who are expected to live less than 6 months may want to consider hospice care. Hospice care is designed to provide the best possible quality of life for people who are near the end of life. You and your family are encouraged to talk with the health care team about hospice care options, which include hospice care at home, a special hospice center, or other health care locations. Nursing care and special equipment can make staying at home a workable option for many families. Learn more about advanced cancer care planning.
After the death of a loved one, many people need support to help them cope with the loss. Learn more about grief and loss.
The next section in this guide is About Clinical Trials. It offers more information about research studies that are focused on finding better ways to care for people with cancer. Use the menu to choose a different section to read in this guide.